ReportWire

Tag: better treatments

  • The Most Mysterious Cells in Our Bodies Don’t Belong to Us

    The Most Mysterious Cells in Our Bodies Don’t Belong to Us

    Some 24 years ago, Diana Bianchi peered into a microscope at a piece of human thyroid and saw something that instantly gave her goosebumps. The sample had come from a woman who was chromosomally XX. But through the lens, Bianchi saw the unmistakable glimmer of Y chromosomes—dozens and dozens of them. “Clearly,” Bianchi told me, “part of her thyroid was entirely male.”

    The reason, Bianchi suspected, was pregnancy. Years ago, the patient had carried a male embryo, whose cells had at some point wandered out of the womb. They’d ended up in his mother’s thyroid—and, almost certainly, a bunch of other organs too—and taken on the identities and functions of the female cells that surrounded them so they could work in synchrony. Bianchi, now the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, was astonished: “Her thyroid had been entirely remodeled by her son’s cells,” she said.

    The woman’s case wasn’t a one-off. Just about every time an embryo implants and begins to grow, it dispatches bits of itself into the body housing it. The depositions begin at least as early as four or five weeks into gestation. And they settle into just about every sliver of our anatomy where scientists have checked—the heart, the lungs, the breast, the colon, the kidney, the liver, the brain. From there, the cells might linger, grow, and divide for decades, or even, as many scientists suspect, for a lifetime, assimilating into the person that conceived them. They can almost be thought of as evolution’s original organ transplant, J. Lee Nelson, of the Fred Hutchinson Cancer Center in Seattle, told me. Microchimerism may be the most common way in which genetically identical cells mature and develop inside two bodies at once.

    These cross-generational transfers are bidirectional. As fetal cells cross the placenta into maternal tissues, a small number of maternal cells migrate into fetal tissues, where they can persist into adulthood. Genetic swaps, then, might occur several times throughout a life. Some researchers believe that people may be miniature mosaics of many of their relatives, via chains of pregnancy: their older siblings, perhaps, or their maternal grandmother, or any aunts and uncles their grandmother might have conceived before their mother was born. “It’s like you carry your entire family inside of you,” Francisco Úbeda de Torres, an evolutionary biologist at the Royal Holloway University of London, told me.

    All of that makes microchimerism—named in homage to the part-lion, part-goat, part-dragon chimera of Greek myth—more common than pregnancy itself. It’s thought to affect every person who has carried an embryo, even if briefly, and anyone who has ever inhabited a womb. Other mammals—mice, cows, dogs, our fellow primates—seem to haul around these cellular heirlooms too. But borrowed cells don’t always show up in the same spots, or in the same numbers. In many cases, microchimeric cells are thought to be present at concentrations on the order of one in 1 million—levels that, “for a lot of biological assays, is approaching or at the limit of detection,” Sing Sing Way, an immunologist and a pediatrician at Cincinnati Children’s Hospital, told me.

    Some scientists have argued that cells so sparse and inconsistent couldn’t possibly have meaningful effects. Even among microchimerism researchers, hypotheses about what these cells do—if anything at all—remain “highly controversial,” Way said. But many experts contend that microchimeric cells aren’t just passive passengers, adrift in someone else’s genomic sea. They are genetically distinct entities in a foreign residence, with their own evolutionary motivations that may clash with their landlord’s. And they might hold sway over many aspects of health: our susceptibility to infectious or autoimmune disease, the success of pregnancies, maybe even behavior. If these cells turn out to be as important as some scientists believe they are, they might be one of the most underappreciated architects of human life.

    Already, researchers have uncovered hints of what these wandering cells are up to. Way’s studies in mice, for instance, suggest that the microchimerism that babies inherit during gestation might help fine-tune their immune system, steeling the newborn body against viral infections; as the rodents age, their mother’s cells may aid in bringing their own pregnancies to term, by helping them see the fetus—made up of half-foreign DNA—as benign, rather than an unfamiliar threat.

    Similarly, inherited microchimerism might help explain why some studies have found that people are better at accepting organs from their mother than from their father, says William Burlingham, a transplant specialist at the University of Wisconsin at Madison. In the early ’90s, Burlingham treated a kidney-transplant patient who had abruptly stopped taking his immunosuppressive medications—a move that should have prompted his body’s rejection of the new organ. But “he was doing fine,” Burlingham told me. The patient’s kidney had come from his mother, whose cells were still circulating in his blood and skin; when his body encountered the transplanted tissues, it saw the newcomers as more of the same.

    Even fetal cells that meander into mothers during pregnancy might buoy the baby’s health. David Haig, an evolutionary biologist at Harvard, thinks that these cells may position themselves to optimally extract resources from Mom: in the brain, to command more attention; in the breast, to stimulate more milk production; in the thyroid, to coax more body heat. The cells, he told me, might also fiddle with a mother’s fertility, extending the interval between births to give the baby more uninterrupted care. Fetal delegates could then serve as informants for future offspring that inhabit the same womb, Úbeda de Torres told me. If later fetuses don’t detect much relatedness between themselves and their older siblings, he said, they might become greedier when siphoning nutrients from their mother’s body, rather than leaving extra behind for future siblings whose paternity may also differ from theirs.

    The perks of microchimerism for mothers have been tougher to pin down. One likely possibility is that the more thoroughly embryonic cells infiltrate the mother’s body, the better she might be able to tolerate her fetus’s tissue, reducing her chances of miscarriage or a high-risk birth. “I really think it’s a baby’s insurance policy on the mom,” Amy Boddy, a biological anthropologist at UC Santa Barbara, told me. “Like, ‘Hey, don’t attack.’” After delivery, the cells that stick around in the mother’s body may ease future pregnancies too (at least those by the same father). Pregnancy complications such as preeclampsia become rarer the more times someone conceives with the same partner. And when mothers send cellular envoys into their babies, they might be able to cut Mom a break by upping a child’s sleepiness, or curbing their fussiness.

    Microchimerism may not always be kind to moms. Nelson and others have found that, long-term, women with more fetal cells are also more likely to develop certain kinds of autoimmune disease, perhaps because their children’s cells are mistakenly reassessed by certain postpartum bodies as unwanted invaders. Nelson’s former postdoctoral fellow Nathalie Lambert, now at the French National Institute of Health and Medical Research, has found evidence in mouse experiments that fetal microchimeric cells may also produce antibodies that can goad attacks on maternal cells, Lambert told me. But the situation is also more complicated than that. “I don’t think they’re bad actors,” Nelson said of the interloping fetal cells. She and her colleagues have also found that fetal cells might sometimes protect against autoimmunity, leading a few conditions, such as rheumatoid arthritis, to actually abate during and shortly after pregnancy.

    In other contexts, too, fetal cells might offer both help and harm to the mother, or neither at all. Fetally derived microchimeric cells have been spotted voyaging into the cardiac tissues of mice who have experienced mid-pregnancy heart attacks, settling the pancreases of newly diabetic mouse moms, and lurking inside human tumors and C-section scars. But scientists aren’t sure whether the foreign cells are causing damage, repairing it, or simply bystanders, discovered in these spots by coincidence.

    These questions are so difficult to answer, Way told me, because microchimeric cells are so challenging to study. They might be in all of us, but they’re still rare, and frequently hidden in tough-to-access internal tissues. Researchers can’t yet say whether the cells actively deploy to predetermined sites or are pulled into specific organs by maternal cells—or just follow the natural flow of blood like river sediments. There’s also no consensus on how much microchimerism a body can tolerate. In a vacuum of evidence, even microchimerism researchers are steeling themselves for a letdown. “A very large part of me is prepared to think that most if not all microchimerism is completely benign,” Melissa Wilson, a computational evolutionary biologist at Arizona State University, told me.

    But if microchimeric cells do have a role to play in autoimmunity or reproductive success, the potential for therapies could be huge. One option, Burlingham told me, might be to infuse organ-transplant patients with cells from their mother, which could, like tiny ambassadors, coax the body into accepting any new tissue. Microchimerism-inspired therapies could help ease the burdens of high-risk pregnancies, Boddy told me, many of which seem to be fueled by the maternal body mounting an inappropriately aggressive immune response. They might also improve the experience of surrogates, who are more likely to experience pregnancy complications such as high blood pressure, preterm birth, and gestational diabetes. The cells’ stem-esque properties could even help researchers design better treatments for genetic diseases in utero; one research group, at UC San Francisco, is pursuing this idea for the blood disorder alpha thalassemia.

    Before those visions can be enacted, some questions need to be resolved. Researchers have unearthed evidence that microchimeric cells from different sources might sometimes compete with, or even displace one another, in bids for dominance. If the same dynamic plays out with future therapies, doctors may need to be careful about which cells they introduce to people and when, or risk losing the precious cargo they infuse. And, perhaps most fundamental, scientists can’t yet say how many microchimeric cells are necessary to exert influence over a specific person’s health—a threshold that will likely determine just how practical these theoretical treatments might be, Kristine Chua, a biological anthropologist at UCSB, told me.

    Even amid these uncertainties, the experts I spoke with stand by microchimerism’s likely importance: The cells are so persistent, so ubiquitous, so evolutionarily ancient, Boddy told me, that they must have an effect. The simple fact that they’re allowed to stick around for decades, while they grow and develop and change, could have a lot to teach us about immunity—and our understanding of ourselves. “In my mind, it does alter my concept of who I am,” Bianchi, who herself has given birth to a son, told me. Although he’s since grown up, she’s never without him, nor he without her.

    Katherine J. Wu

    Source link

  • The ‘End’ of COVID Is Still Far Worse Than We Imagined

    The ‘End’ of COVID Is Still Far Worse Than We Imagined

    When is the pandemic “over”? In the early days of 2020, we envisioned it ending with the novel coronavirus going away entirely. When this became impossible, we hoped instead for elimination: If enough people got vaccinated, herd immunity might largely stop the virus from spreading. When this too became impossible, we accepted that the virus would still circulate but imagined that it could become, optimistically, like one of the four coronaviruses that cause common colds or, pessimistically, like something more severe, akin to the flu.

    Instead, COVID has settled into something far worse than the flu. When President Joe Biden declared this week, “The pandemic is over. If you notice, no one’s wearing masks,” the country was still recording more than 400 COVID deaths a day—more than triple the average number from flu.

    This shifting of goal posts is, in part, a reckoning with the biological reality of COVID. The virus that came out of Wuhan, China, in 2019 was already so good at spreading—including from people without symptoms—that eradication probably never stood a chance once COVID took off internationally. “I don’t think that was ever really practically possible,” says Stephen Morse, an epidemiologist at Columbia. In time, it also became clear that immunity to COVID is simply not durable enough for elimination through herd immunity. The virus evolves too rapidly, and our own immunity to COVID infection fades too quickly—as it does with other respiratory viruses—even as immunity against severe disease tends to persist. (The elderly who mount weaker immune responses remain the most vulnerable: 88 percent of COVID deaths so far in September have been in people over 65.) With a public weary of pandemic measures and a government reluctant to push them, the situation seems unlikely to improve anytime soon. Trevor Bedford, a virologist at the Fred Hutchinson Cancer Center, estimates that COVID will continue to exact a death toll of 100,000 Americans a year in the near future. This too is approximately three times that of a typical flu year.


    I keep returning to the flu because, back in early 2021, with vaccine excitement still fresh in the air, several experts told my colleague Alexis Madrigal that a reasonable threshold for lifting COVID restrictions was 100 deaths a day, roughly on par with flu. We largely tolerate, the thinking went, the risk of flu without major disruptions to our lives. Since then, widespread immunity, better treatments, and the less virulent Omicron variant have together pushed the risk of COVID to individuals down to a flu-like level. But across the whole population, COVID is still killing many times more people than influenza is, because it is still sickening so many more people.

    Bedford told me he estimates that Omicron has infected 80 percent of Americans. Going forward, COVID might continue to infect 50 percent of the population every year, even without another Omicron-like leap in evolution. In contrast, flu sickens an estimated 10 to 20 percent of Americans a year. These are estimates, because lack of testing hampers accurate case counts for both diseases, but COVID’s higher death toll is a function of higher transmission. The tens of thousands of recorded cases—likely hundreds of thousands of actual cases every day—also add to the burden of long COVID.

    The challenge of driving down COVID transmission has also become clearer with time. In early 2021, the initially spectacular vaccine-efficacy data bolstered optimism that vaccination could significantly dampen transmission. Breakthrough cases were downplayed as very rare. And they were—at first. But immunity to infection is not durable against common respiratory viruses. Flu, the four common-cold coronaviruses, respiratory syncytial virus (RSV), and others all reinfect us over and over again. The same proved true with COVID. “Right at the beginning, we should have made that very clear. When you saw 95 percent against mild disease, with the trials done in December 2020, we should have said right then this is not going to last,” says Paul Offit, the director of the Vaccine Education Center at Children’s Hospital of Philadelphia. Even vaccinating the whole world would not eliminate COVID transmission.

    This coronavirus has also proved a wilier opponent than expected. Despite a relatively slow rate of mutation at the beginning of the pandemic, it soon evolved into variants that are more inherently contagious and better at evading immunity. With each major wave, “the virus has only gotten more transmissible,” says Ruth Karron, a vaccine researcher at Johns Hopkins. The coronavirus cannot keep becoming more transmissible forever, but it can keep changing to evade our immunity essentially forever. Its rate of evolution is much higher than that of other common-cold coronaviruses. It’s higher than that of even H3N2 flu—the most troublesome and fastest-evolving of the influenza viruses. Omicron, according to Bedford, is the equivalent of five years of H3N2 evolution, and its subvariants are still outpacing H3N2’s usual rate. We don’t know how often Omicron-like events will happen. COVID’s rate of change may eventually slow down when the virus is no longer novel in humans, or it may surprise us again.

    In the past, flu pandemics “ended” after the virus swept through so much of the population that it could no longer cause huge waves. But the pandemic virus did not disappear; it became the new seasonal-flu virus. The 1968 H3N2 pandemic, for example, seeded the H3N2 flu that still sickens people today. “I suspect it’s probably caused even more morbidity and mortality in all those years since 1968,” Morse says. The pandemic ended, but the virus continued killing people.

    Ironically, H3N2 did go away during the coronavirus pandemic. Measures such as social distancing and masking managed to almost entirely eliminate the flu. (It has not disappeared entirely, though, and may be back in full force this winter.) Cases of other respiratory viruses, such as RSV, also plummeted. Experts hoped that this would show Americans a new normal, where we don’t simply tolerate the flu and other respiratory illnesses every winter. Instead, the country is moving toward a new normal where COVID is also something we tolerate every year.

    In the same breath that President Biden said, “The pandemic is over,” he went on to say, “We still have a problem with COVID. We’re still doing a lot of work on it.” You might see this as a contradiction, or you might see it as how we deal with every other disease—an attempt at normalizing COVID, if you will. The government doesn’t treat flu, cancer, heart disease, tuberculosis, hepatitis C, etc., as national emergencies that disrupt everyday life, even as the work continues on preventing and treating them. The U.S.’s COVID strategy certainly seems to be going in that direction. Broad restrictions such as mask mandates are out of the question. Interventions targeted at those most vulnerable to severe disease exist, but they aren’t getting much fanfare. This fall’s COVID-booster campaign has been muted. Treatments such as bebtelovimab and Evusheld remain on shelves, underpublicized and underused.

    At the same time, hundreds of Americans are still dying of COVID every day and will likely continue to die of COVID every day. A cumulative annual toll of 100,000 deaths a year would still make COVID a top-10 cause of death, ahead of any other infectious disease. When the first 100,000 Americans died of COVID, in spring 2020, newspapers memorialized the grim milestone. The New York Times devoted its entire front page to chronicling the lives lost to COVID. It might have been hard to imagine, back in 2020, that the U.S. would come to accept 100,000 people dying of COVID every year. Whether or not that means the pandemic is over, the second part of the president’s statement is harder to argue with: COVID is and will remain a problem.

    Sarah Zhang

    Source link